Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Nov 25;64(6):881–885. doi: 10.1136/ard.2004.026443

Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis

N Bellamy 1, M Bell 1, C Goldsmith 1, D Pericak 1, V Walker 1, J Raynauld 1, G Torrance 1, P Tugwell 1, R Polisson 1
PMCID: PMC1755531  PMID: 15564311

Abstract

Objective: A secondary analysis of a previously conducted one year randomised controlled trial to evaluate the capacity of responder criteria based on the WOMAC index to detect between treatment group differences.

Methods: 255 patients with knee osteoarthritis were randomised to "appropriate care with hylan G-F 20" (AC+H) or "appropriate care without hylan G-F 20" (AC). In the original analysis, two definitions of patient response from baseline to month 12 were used: (1) at least a 20% reduction in WOMAC pain score (WOMAC 20P); (2) at least a 20% reduction in WOMAC pain score and at least a 20% reduction in either WOMAC function or stiffness score (WOMAC 20PFS). For this analysis, a responder was identified using 50% and 70% minimum clinically important response levels to investigate how increasing response affects the ability to detect treatment group differences.

Results: The hylan G-F 20 group had numerically more responders using all patient responder criteria. Increasing the response level from 20% to 50% detected similar differences between treatment groups (25% to 29%). Increasing the response level to 70% reduced the differences between treatment groups (11% to 12%) to a point where the differences were not significant after Bonferroni adjustment.

Conclusions: These results provide evidence for incorporating response levels (WOMAC 50) in clinical trials. While differences at the highest threshold (WOMAC 70) were not statistically detectable, an appropriately powered study may be capable of detecting differences even at this very high level of improvement.

Full Text

The Full Text of this article is available as a PDF (72.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson Jennifer J., Bolognese James A., Felson David T. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum. 2003 Nov;48(11):3031–3038. doi: 10.1002/art.11293. [DOI] [PubMed] [Google Scholar]
  2. Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., Altman R., Brandt K., Dougados M., Lequesne M. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol. 1997 Apr;24(4):799–802. [PubMed] [Google Scholar]
  3. Bombardier C., Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol. 1982 Sep-Oct;9(5):753–757. [PubMed] [Google Scholar]
  4. Cohen Stanley, Hurd Eric, Cush John, Schiff Michael, Weinblatt Michael E., Moreland Larry W., Kremer Joel, Bear Moraye B., Rich William J., McCabe Dorothy. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar;46(3):614–624. doi: 10.1002/art.10141. [DOI] [PubMed] [Google Scholar]
  5. Dougados M., Leclaire P., van der Heijde D., Bloch D. A., Bellamy N., Altman R. D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage. 2000 Nov;8(6):395–403. doi: 10.1053/joca.2000.0361. [DOI] [PubMed] [Google Scholar]
  6. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  7. Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
  8. Felson D. T., Anderson J. J., Lange M. L., Wells G., LaValley M. P. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998 Sep;41(9):1564–1570. doi: 10.1002/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  9. Goldsmith C. H., Boers M., Bombardier C., Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993 Mar;20(3):561–565. [PubMed] [Google Scholar]
  10. Hochberg M. C., Altman R. D., Brandt K. D., Clark B. M., Dieppe P. A., Griffin M. R., Moskowitz R. W., Schnitzer T. J. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995 Nov;38(11):1541–1546. doi: 10.1002/art.1780381104. [DOI] [PubMed] [Google Scholar]
  11. Kalden J. R., Schattenkirchner M., Sörensen H., Emery P., Deighton C., Rozman B., Breedveld F. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum. 2003 Jun;48(6):1513–1520. doi: 10.1002/art.11015. [DOI] [PubMed] [Google Scholar]
  12. Kremer Joel M., Weinblatt Michael E., Bankhurst Arthur D., Bulpitt Ken J., Fleischmann Roy M., Jackson Christopher G., Atkins Kelly M., Feng Anyang, Burge Daniel J. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003 Jun;48(6):1493–1499. doi: 10.1002/art.11142. [DOI] [PubMed] [Google Scholar]
  13. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  14. Pham Thao, Van Der Heijde Désirée, Lassere Marissa, Altman Roy D., Anderson Jennifer J., Bellamy Nicholas, Hochberg Marc, Simon Lee, Strand Vibeke, Woodworth Thasia. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol. 2003 Jul;30(7):1648–1654. [PubMed] [Google Scholar]
  15. Raynauld J-P, Torrance G. W., Band P. A., Goldsmith C. H., Tugwell P., Walker V., Schultz M., Bellamy N., Canadian Knee OA Study Group A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002 Jul;10(7):506–517. doi: 10.1053/joca.2002.0798. [DOI] [PubMed] [Google Scholar]
  16. Torrance G. W., Raynauld J. P., Walker V., Goldsmith C. H., Bellamy N., Band P. A., Schultz M., Tugwell P., Canadian Knee OA Study Group A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage. 2002 Jul;10(7):518–527. doi: 10.1053/joca.2001.0513. [DOI] [PubMed] [Google Scholar]
  17. Weisman Michael H., Moreland Larry W., Furst Daniel E., Weinblatt Michael E., Keystone Edward C., Paulus Harold E., Teoh Leah S., Velagapudi Raja B., Noertersheuser Peter A., Granneman G. Richard. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003 Jun;25(6):1700–1721. doi: 10.1016/s0149-2918(03)80164-9. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES